secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioXcel Therapeutics, Inc. (BTAI)
CIK:        0001720893
Form:       8-K
Filed at:   2025-09-15T23:59:59+00:00
Accession:  0001104659-25-089773
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 7.01, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

BioXcel completes enrollment for mCGI-S/PEC study; sNDA submission expected Q1 2026
--------------------------------------------------------------------------------

- Open-label study of ~30 patients evaluating mCGI-S vs PEC scale enrolled on Sept 13, 2025; results due Q4 2025.
- sNDA for BXCL501 SERENITY At-Home program planned for Q1 2026, incorporating this and prior Phase 3 safety data.
- Raised $37.3M from July 1 to Sept 15, 2025 via ATM ($27.6M) and warrant exercises ($9.7M).
- As of Sept 12, 2025, shares outstanding totaled 19,646,801; cash expected to fund operations into Q1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720893/000110465925089773/0001104659-25-089773-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720893/000110465925089773/tm2526080d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-089773

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer